Evidence map›Paper›PMID 27141334›Full record

ArticleOncoimmunology2016

Novel therapy of prostate cancer employing a combination of viral-based immunotherapy and a small molecule BH3 mimetic.

Siddik Sarkar, Anjan Pradhan, Swadesh K Das, Luni Emdad, Devanand Sarkar, Maurizio Pellecchia, Paul B Fisher

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Oncoimmunology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Review
  3. Nanoparticle Design Strategies for Effective Cancer Immunotherapy.Journal of Biomedicine (Sydney, NSW) · 2017
    Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Siddik SarkarDepartment of Human and Molecular Genetics, Virginia Commonwealth University , Richmond, VA, USA.
Anjan PradhanDepartment of Human and Molecular Genetics, Virginia Commonwealth University , Richmond, VA, USA.
Swadesh K DasDepartment of Human and Molecular Genetics, Virginia Commonwealth University, Richmond, VA, USA; VCU Institute of Molecular Medicine, Virginia Commonwealth University, Richmond, VA, USA; VCU Massey Cancer Center, School of Medicine, Virginia Commonwealth University, Richmond, VA, USA.
Luni EmdadDepartment of Human and Molecular Genetics, Virginia Commonwealth University, Richmond, VA, USA; VCU Institute of Molecular Medicine, Virginia Commonwealth University, Richmond, VA, USA; VCU Massey Cancer Center, School of Medicine, Virginia Commonwealth University, Richmond, VA, USA.
Devanand SarkarDepartment of Human and Molecular Genetics, Virginia Commonwealth University, Richmond, VA, USA; VCU Institute of Molecular Medicine, Virginia Commonwealth University, Richmond, VA, USA; VCU Massey Cancer Center, School of Medicine, Virginia Commonwealth University, Richmond, VA, USA.
Maurizio PellecchiaSanford-Burnham-Prebys Discovery Institute , La Jolla, CA, USA.
Paul B FisherDepartment of Human and Molecular Genetics, Virginia Commonwealth University, Richmond, VA, USA; VCU Institute of Molecular Medicine, Virginia Commonwealth University, Richmond, VA, USA; VCU Massey Cancer Center, School of Medicine, Virginia Commonwealth University, Richmond, VA, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cancer-selective viral replication and delivery of a therapeutic immunomodulating, cancer-selective killing cytokine (

Indexed as

Cancer Terminator Virus (CTV)MDA-7/IL-24Primary and Metastatic Prostate CancerSabutoclaxTumor-Specific Apoptosis; ImmunotherapyUltrasound-Targeted Microbubble-Destruction (UTMD)

Identifiers

PMID27141334
PMCPMC4839355

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.